BioClec launches with backing from Sofinnova Partners to pioneer breakthrough Alzheimer’s Therapies
- Co-founded by Dr. Marco Colonna, a global expert in neuroimmunology and Alzheimer’s research
- Led by CEO Gabriella Camboni, an eminent serial entrepreneur with a track record of successful biotech ventures
MILAN, Italy – March 18, 2025 – BioClec, a cutting-edge biotechnology company focused on breakthrough therapies for Alzheimer’s disease (AD), announces its launch today. Emerging from Sofinnova Partners’ €165M Biovelocita II accelerator program, BioClec is developing novel therapies targeting microglia, the brain’s immune cells, to treat Alzheimer’s disease, the most common form of dementia. AD, which affects millions worldwide, progressively impairs memory and cognitive functions, ultimately depriving patients of their ability to perform daily activities.
